Hennion & Walsh Asset Management, Inc. Verona Pharma PLC Transaction History
Hennion & Walsh Asset Management, Inc.
- $1.89 Billion
- Q2 2024
A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Verona Pharma PLC stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 135,629 shares of VRNA stock, worth $4.34 Million. This represents 0.1% of its overall portfolio holdings.
Number of Shares
135,629
Previous 67,365
101.33%
Holding current value
$4.34 Million
Previous $1.08 Million
81.07%
% of portfolio
0.1%
Previous 0.06%
Shares
3 transactions
Others Institutions Holding VRNA
# of Institutions
137Shares Held
66.7MCall Options Held
495KPut Options Held
486K-
Ra Capital Management, L.P. Boston, MA7.63MShares$244 Million1.66% of portfolio
-
Nea Management Company, LLC Timonium, MD5.58MShares$179 Million7.62% of portfolio
-
Deep Track Capital, LP Greenwich, CT4MShares$128 Million1.9% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.55MShares$114 Million7.58% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.31MShares$106 Million2.82% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $1.95B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...